Stock events for BioAge Labs, Inc. (BIOA)
In December 2024, BioAge Labs discontinued its Phase 2 STRIDES study of azelaprag due to safety concerns, leading to a stock price drop. In January 2025, the company faced a class-action lawsuit from shareholders. In November 2025, BioAge reported collaboration revenue of $2.1 million for Q3 2025 and anticipated initial single ascending dose (SAD) data for BGE-102 by the end of 2025. In January 2026, BioAge announced a public offering of common stock, generating approximately $115.0 million in gross proceeds. In December 2025, BioAge reported positive interim Phase 1 data for BGE-102. In February 2026, Oppenheimer initiated coverage on BioAge Labs with an "outperform" rating, and Jefferies upgraded BioAge Labs to a "Buy", contributing to a stock price increase.
Demand Seasonality affecting BioAge Labs, Inc.’s stock price
BioAge Labs' demand is not subject to typical seasonal fluctuations. Demand for its drug candidates, once commercialized, will be driven by the prevalence of the targeted metabolic diseases, the efficacy and safety of the drugs, and market adoption.
Overview of BioAge Labs, Inc.’s business
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases like obesity by targeting the biology of human aging. Their pipeline includes BGE-102 (formerly Azelaprag), an NLRP3 inhibitor in Phase 1 development for obesity and cardiovascular risk factors, with plans to expand into ophthalmology for diabetic macular edema. They are also developing APJ agonists for obesity, showing potential for significant weight loss, with an IND submission anticipated by the end of 2026. Additionally, BioAge utilizes an AI platform to identify novel drug targets.
BIOA’s Geographic footprint
BioAge Labs, Inc. is headquartered in Emeryville, California, United States, and focuses its operations on direct research and development with a global market focus.
BIOA Corporate Image Assessment
BioAge Labs' brand reputation was negatively impacted by the halting of its Phase 2 obesity drug trial and subsequent lawsuits alleging misrepresented drug safety. However, positive interim Phase 1 data for BGE-102, collaborations with Novartis and Lilly, and positive analyst coverage suggest a potential recovery in reputation.
Ownership
BioAge Labs, Inc. has significant institutional ownership, with 157 institutional owners holding 22,074,602 shares as of March 4, 2026, representing 64.22% of the company. Major institutional owners include AH Capital Management, L.L.C., Sofinnova Investments, Inc., and BlackRock, Inc. Individual owners and insiders hold 27.58% of the company's stock, with CEO Kristen Fortney being a notable individual owner.
